See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Avadel Pharmaceuticals PLC. (AVDL) - free report >>
Green Brick Partners, Inc. (GRBK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avadel Pharmaceuticals PLC. (AVDL) - free report >>
Green Brick Partners, Inc. (GRBK) - free report >>
Image: Bigstock
Top Ranked Momentum Stocks to Buy for December 9th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 9th:
Green Brick Partners, Inc. (GRBK - Free Report) : This homebuilding and land development company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.8% over the last 60 days.
Green Brick Partners, Inc. Price and Consensus
Green Brick Partners, Inc. price-consensus-chart | Green Brick Partners, Inc. Quote
Green Brick Partners’ shares gained 5.3% over the last one month more than S&P 500’s gain of 1.9%. The company possesses a Momentum Score of B.
Green Brick Partners, Inc. Price
Green Brick Partners, Inc. price | Green Brick Partners, Inc. Quote
Intellicheck, Inc. (IDN - Free Report) : This technology company that develops, integrates and markets threat identification and identity authentication solutions has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.
Intellicheck Mobilisa, Inc. Price and Consensus
Intellicheck Mobilisa, Inc. price-consensus-chart | Intellicheck Mobilisa, Inc. Quote
Intellicheck’s shares gained 13.6% over the last one month. The company possesses a Momentum Score of B.
Intellicheck Mobilisa, Inc. Price
Intellicheck Mobilisa, Inc. price | Intellicheck Mobilisa, Inc. Quote
Aquestive Therapeutics, Inc. (AQST - Free Report) : This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.9% over the last 60 days.
Aquestive Therapeutics, Inc. Price and Consensus
Aquestive Therapeutics, Inc. price-consensus-chart | Aquestive Therapeutics, Inc. Quote
Aquestive Therapeutics’ shares gained 33.8% over the last one month. The company possesses a Momentum Score of A.
Aquestive Therapeutics, Inc. Price
Aquestive Therapeutics, Inc. price | Aquestive Therapeutics, Inc. Quote
Avadel Pharmaceuticals plc (AVDL - Free Report) : This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.9% over the last 60 days.
Avadel Pharmaceuticals PLC. Price and Consensus
Avadel Pharmaceuticals PLC. price-consensus-chart | Avadel Pharmaceuticals PLC. Quote
Avadel Pharmaceuticals’ shares gained 28.6% over the last one month. The company possesses a Momentum Score of A.
Avadel Pharmaceuticals PLC. Price
Avadel Pharmaceuticals PLC. price | Avadel Pharmaceuticals PLC. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>